Compare FSUN & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSUN | TNDM |
|---|---|---|
| Founded | 1892 | 2006 |
| Country | United States | United States |
| Employees | 1186 | 2500 |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.1B |
| IPO Year | N/A | 2013 |
| Metric | FSUN | TNDM |
|---|---|---|
| Price | $35.52 | $17.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 19 |
| Target Price | ★ $45.00 | $28.00 |
| AVG Volume (30 Days) | 141.0K | ★ 2.8M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | $79.34 | $8.11 |
| Revenue Next Year | $14.67 | $11.85 |
| P/E Ratio | $11.30 | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $29.95 | $10.00 |
| 52 Week High | $42.34 | $29.65 |
| Indicator | FSUN | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 52.21 |
| Support Level | $34.44 | $11.86 |
| Resistance Level | $37.12 | $21.68 |
| Average True Range (ATR) | 0.87 | 1.11 |
| MACD | 0.03 | 0.39 |
| Stochastic Oscillator | 38.49 | 80.07 |
Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments; Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.